IGEA Pharma NV
F:3B5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
IGEA Pharma NV
F:3B5
|
NL |
|
Fox Factory Holding Corp
NASDAQ:FOXF
|
US |
|
V
|
Vodacom Group Ltd
JSE:VOD
|
ZA |
|
First Bancorp (North Carolina)
NASDAQ:FBNC
|
US |
|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
US |
|
Avix Technologies Inc
OTC:AVIX
|
CA |
|
Kohls Corp
NYSE:KSS
|
US |
|
Bls International Services Ltd
NSE:BLS
|
IN |
|
B
|
Bioptro Inc
KOSDAQ:222160
|
KR |
Income Statement
Earnings Waterfall
IGEA Pharma NV
Income Statement
IGEA Pharma NV
| Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Jun-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||
| Revenue |
0
N/A
|
0
+3%
|
0
+63%
|
0
+4%
|
0
-41%
|
0
-63%
|
0
+3 477%
|
0
+63%
|
0
-35%
|
0
+109%
|
0
-18%
|
0
N/A
|
|
| Gross Profit | |||||||||||||
| Cost of Revenue |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
|
| Gross Profit |
(0)
N/A
|
(0)
+16%
|
(0)
-1%
|
(0)
-45%
|
(0)
+26%
|
(0)
-31%
|
(0)
-39%
|
(0)
+44%
|
(0)
+18%
|
(0)
+86%
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||
| Operating Expenses |
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
|
| Selling, General & Administrative |
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
|
| Other Operating Expenses |
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(1)
N/A
|
(1)
-14%
|
(1)
-124%
|
(2)
-34%
|
(2)
-6%
|
(2)
+16%
|
(2)
-36%
|
(1)
+60%
|
(1)
-11%
|
(1)
-12%
|
(1)
+17%
|
(0)
+65%
|
|
| Pre-Tax Income | |||||||||||||
| Interest Income Expense |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(1)
N/A
|
(1)
-11%
|
(1)
-123%
|
(2)
-34%
|
(2)
-11%
|
(2)
+10%
|
(2)
-34%
|
(1)
+56%
|
(1)
-18%
|
(1)
+2%
|
(1)
+18%
|
(0)
+65%
|
|
| Net Income | |||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(0)
N/A
|
(1)
-13%
|
(1)
-165%
|
(2)
-34%
|
(2)
-11%
|
(2)
+10%
|
(2)
-34%
|
(1)
+56%
|
(1)
-19%
|
(1)
+5%
|
(1)
+20%
|
1
N/A
|
|
| EPS (Diluted) |
-0.02
N/A
|
-0.02
N/A
|
-0.06
-200%
|
-0.07
-17%
|
-0.08
-14%
|
-0.07
+12%
|
-0.1
-43%
|
-0.04
+60%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|